The London-based bladder care startup secured backing from Eka VC and Joyance to drive its upcoming launch in the United States.
"Since launch, we’ve improved the lives of tens of thousands of people suffering from bladder issues with treatments and education tools. This investment will be critical in us achieving this mission, and expanding our services to the US, where 75m people struggle with these issues. I’m incredibly happy to welcome Eka Ventures and Joyance – who are aligned on our healthcare mission – and to continue our partnership with Samos VC."
BGF contributed £3m to the oversubscribed round as the digital mental health provider scales its operations.
"Kooth is a great example of a high-quality business with a proven business model, a significant recurring revenue stream, and now international growth potential. We have a strong conviction in the management team’s ability to execute the step-change in the scale of the business following the recent US contract win, which is a clear demonstration of Kooth’s credibility and expertise in its field. This is an exceptional achievement for a UK-based business that has purpose at its core, and we’re delighted to be playing a part in its continued expansion."
The investment was led by Gresham House Ventures and will be used to scale technology and sales functions.
"Mable’s mission has always been to design therapy that puts children at its core, giving them the best chance to reach their full potential. Our pioneering technology has already helped thousands of families across the UK, and with this investment by Gresham House Ventures we can take this support even further."
The funding round was led by Octopus Ventures with backing from JamJar and Forward Partners.
"This latest injection of funding – from experienced investors with a proven track record of backing successful fertility and femtech businesses – will enable us to get our pioneering treatment in the hands of the people who need it most. We can’t wait for people to try it."
The London based healthtech startup secured backing from investors including Entrepreneur First and Form Ventures to expand its platform into clinical settings.
"Our technology is revolutionary. By combining cutting edge neuroscience and ethical, explainable AI, we have built a tool that can help people get an accurate diagnosis and effective treatment plan in place faster than ever before. It’s all about arming clinicians with the very best tools so that they can do the very best by their patients. We’re so grateful for the support our investors have shown us so far; and we look forward to this next stage of our journey as we look to optimise and expand our technology and get it in the hands of the people who need it most."
